Colorectal Cancer Membrane Protein Interactomics [A Major Discriminator Of Clinical Outcome]
Funder
National Health and Medical Research Council
Funding Amount
$643,778.00
Summary
This project studies the molecular causes of colorectal cancer (CRC) malignancy because CRC is the 2nd most common malignancy by incidence and cause of death in the Western world. It currently results in 13.1% of Australian cancer deaths. The aim of this NHMRC project is to gain a detailed understanding of how particular cell membrane proteins interact with each to give cancer cells the ability to invade and spread.
Novel Targeting Of Therapy-resistant Prostate Cancer Cells.
Funder
National Health and Medical Research Council
Funding Amount
$596,978.00
Summary
Prostate cancer is treated by removing male hormones (androgens). Although the bulk of the tumour regresses, some cells remain and the cancer often grows back in an aggressive form. We will study new ways to eliminate therapy resistant cancer cells and thereby provide more lasting treatments for prostate cancer. Ultimately, we hope to inform the design of ground-breaking clinical trials that could re-shape the treatment paradigm of advanced prostate cancer.
Targeting Homeobox Genes In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$658,739.00
Summary
Acute myeloid leukaemia (AML) is a common blood cancer with dire clinical prognosis due to a lack of targeted molecular therapies. In this proposal we will identify new ways of targeting transcription factor proteins that are overexpressed in AML and promote leukaemia by repressing normal cellular growth controls. This may lead to novel methods to target leukaemic stem cells to specifically eliminate myeloid leukemia
For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 years have produced a powerful fourth treatment: the patient's own immune system.The long standing collaborations and synergies of our multi-disciplinary teams have already underpinned many recent advances in immune-based therapies: we are now poised to develop several further immunotherapies and on track to test them in patients during the term of this grant.
KLK4 Is A Master Regulator Of Tumour Microenvironment Remodelling In Prostate Cancer And Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$596,305.00
Summary
The current biomarker for prostate cancer, PSA, belongs to a large family of related proteins called KLK enzymes. We have evidence that one of these enzymes, KLK4, regulates many different pathways involved in tumour spreading especially to bones. This project will determine the specific components involved with a view to finding better biomarkers of tumour spread and bone metastasis and designing better treatments for these aspects of the disease.
A Novel Protease And Growth Factor Regulated Signalling System In Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$856,743.00
Summary
Ovarian cancer is the leading cause of gynaecologic cancer death. Our project focuses on the role in ovarian cancer of a cellular receptor called CDCP1. We have previously shown that CDCP1 promotes growth and spread of ovarian tumours. Recently we have generated new data indicating that CDCP1’s activity is markedly increased by other proteins called proteases and growth factors. In this project we will define how these new pathways function, and if their blockade impedes ovarian cancer.
Identiification Of Novel Biomarkers And Therapeutic Targets For The Treatment Of Pancreatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$362,463.00
Summary
Pancreatic cancer is a devastating disease with an appalling prognosis - only 6% of patient survive 5 years after diagnosis. The aim of this research is to use new technologies to find out how pancreatic cells become malignant and why the cancerous cells are so drug resistant. The goal is to ideantify cell markers to guide drug treatment design and new targets for antibody therapy. By combining emerging technologies we hope to achieve break-through outcomes in the treatment of pancreatic cancer.
In melanoma we hypothesise there is a series of as yet unidentified gene fusions which provide oncogenic stimulatory signals that promote tumour growth and that these novel fusion products are excellent targets for the design of new therapies to treat melanoma. The aims of this study are to identify oncogenic fusions in melanoma, to assess which of these are recurrent, and to demonstrate that the resulting fusion proteins provide a selective growth and-or survival advantage to the tumour cell.
Activating Transcription Factor 3 And Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$767,794.00
Summary
We have shown that the transcription factor ATF3 suppresses bladder cancer spread. Turning off ATF3 is associated with disease progression in bladder and colorectal cancer. We will test whether levels of ATF3 can be used as a prognostic maker for disease progression, investigate the mechanisms underlying the actions of ATF3 in bladder and colorectal cancer and test whether therapeutically activating ATF3 can inhibit cancer progression.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE100100217
Funder
Australian Research Council
Funding Amount
$450,000.00
Summary
In-Vivo Multispectral and X-ray Micro-CT Imaging: Founding a Western Australian small animal imaging core facility. The Western Australian Small Animal Imaging facility will provide wide access for the West Australian research community to a multimodality functional and dynamic core bioimaging facility to characterise in-vivo animal models, including extensive postgraduate research training. Wide-ranging research outcomes of national and community benefit include imaging tumour development, bone ....In-Vivo Multispectral and X-ray Micro-CT Imaging: Founding a Western Australian small animal imaging core facility. The Western Australian Small Animal Imaging facility will provide wide access for the West Australian research community to a multimodality functional and dynamic core bioimaging facility to characterise in-vivo animal models, including extensive postgraduate research training. Wide-ranging research outcomes of national and community benefit include imaging tumour development, bone metabolism (osteoporosis), neural function (Alzheimer's disease) and regeneration, and infection mechanisms in live animals, which will result in improvements in human health. Imaging and monitoring coral growth, fish age, and soil structure will improve the economics and sustainability of Australia's marine ecosystems and agricultural food production.Read moreRead less